Drug intelligence / Profile preview

UHE-105

Development stage: Phase 2
Lead developer: Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

UHE-105 is an investigational drug developed by Therapeutics, Inc. for dermatological use, specifically as a topical shampoo formulation. Its primary indication is scalp psoriasis, a chronic inflammatory skin condition affecting the scalp. The drug has undergone at least one Phase 2 clinical trial to evaluate its safety and efficacy in subjects with scalp psoriasis. While the precise mechanism of action and molecular target are not publicly disclosed, UHE-105 is being explored within the therapeutic areas of skin and musculoskeletal diseases[1][2].

Beyond the preview

Go deeper on UHE-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UHE-105.

Explore the full profile